Overcoming Resistance To Frontline Immunotherapy In Kidney Cancer
Overcoming Resistance To Frontline Immunotherapy In Kidney Cancer Information Guide
Introduction on Overcoming Resistance To Frontline Immunotherapy In Kidney Cancer
Tian Zhang, MD, UT Southwestern Medical Center, Dallas, TX, comments on the limitations of current Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses Panelists Robert A. Figlin, MD, and Eric Jonasch, MD, provide insight on the implications of Current clinical trials are examining the possibility of giving Martin H. Voss, MD, and Thomas Hutson, DO, PharmD, FACP, discuss the evolving role of tyrosine kinase inhibitor therapy in ... Are you the 33%? Donate to support our mission today: ...
Panelists Robert A. Figlin, MD; Michael B. Atkins, MD; and Sandy Srinivas, MD, discuss the efficacy and safety of Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, ...
Key Details
Latest News
Full Guide
Data is compiled from public records and verified media reports.
Last Updated: May 24, 2026
Summary
Disclaimer: Disclaimer: Details estimates are based on publicly available data, media reports, and financial analysis. Actual numbers may vary.
